# Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer

> **NCT03555877** · PHASE2 · COMPLETED · sponsor: **GBG Forschungs GmbH** · enrollment: 56 (actual)

## Conditions studied

- Breast Cancer Metastatic

## Interventions

- **DRUG:** Ribociclib
- **DRUG:** Anastrozole
- **DRUG:** Letrozole
- **DRUG:** Exemestane
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT03555877
- **Lead sponsor:** GBG Forschungs GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-15
- **Primary completion:** 2022-07-21
- **Final completion:** 2022-07-21
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2023-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03555877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03555877, "Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03555877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*